PF-03654746

PF-03654746 is a potent and selective small molecule antagonist of the histamine H3 receptor, developed by Pfizer. It has been investigated in clinical trials for several central nervous system and allergy-related indications, including attention deficit hyperactivity disorder (ADHD), Tourette syndrome, narcolepsy, excessive daytime sleepiness, schizophrenia, Alzheimer's disease, and allergic rhinitis. The drug acts by blocking the histamine H3 receptor—a presynaptic autoreceptor that modulates the release of histamine and other neurotransmitters—potentially improving cognitive function and reducing symptoms associated with these disorders. Clinical development reached phase II for some indications but was discontinued or not pursued further for others[1][2][3][4][5][7].

Other names

N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]cyclobutane-1-carboxamideG3QE979K1XG-3QE979K1XG 3QE979K1X